

EV52461502045
Express Mail Label Number

3/4/05
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
COPPOLA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP 03/03466

FILED: 2 APRIL 2003

U.S. APPLICATION NO: 10/510,026

35 USC §371 DATE: *10/02/03*

FOR: 5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE
DERIVATIVES

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The PTO did not receive the following
listed Item(s) for *US* and *NPL*

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Paivi Kukkola
Agent for Applicants
Reg. No. 50,499

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7875

Date: March 4, 2005

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32444A
APPLICATION NO.
10/510,026
APPLICANT
COPPOLA ET AL.
FILING DATE
OCTOBER 1, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,958,957	9/28/99	Anderson et al.	514	364	4/16/97
	AB	5,972,978	10/26/99	Anderson et al.	514	361	2/19/99
	AC	6,063,800	5/16/00	Anderson et al.	514	369	2/19/99
	AD	6,080,770	6/27/00	Anderson et al.	514	359	2/19/99
	AE	5,162,340	11/10/92	Chakravarty et al.	514	309	5/10/91
	AF	5,281,614	1/25/94	Ashton et al.	514	359	11/2/92
	AG	5,412,097	5/2/95	Chakravarty et al.	546	118	9/2/92
	AH	5,972,978	10/26/99	Andersen et al.	514	361	2/19/99
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
*	AJ	WO 97/40017	10/30/97	PCT			<input type="checkbox"/> <input checked="" type="checkbox"/>
*	AK	WO 01/19831	3/22/01	PCT			<input type="checkbox"/> <input checked="" type="checkbox"/>
	AL	0 512 870	11/11/92	EP			<input type="checkbox"/> <input checked="" type="checkbox"/>
	AM	WO 92/20687	11/26/92	PCT			<input type="checkbox"/> <input checked="" type="checkbox"/>
	AN						<input type="checkbox"/> <input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AO	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. Vol. 3, pp 290-300 (2001)
*	AP	Bright et al., "Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma" Journal of Immunological Methods, vol. 207, pages 23-31(1997),
	AQ	Abstract , Eberle et al., "Preparation of microbiocidal N-phenyl-N [4- (-pyridyl)-pyrimidin-2-yl] amines
	AR	Ducry et al., "Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and evaluation of their affinity for MHC Class-II Proteins", Helvetica Chimica, Acta, Vol. 82, No. 12, pp. 2432-2447 (1999)
*	AS	Mantegani et al., "Synthesis and Antihypertensive Activity of 2,4-dioxoimidazolidin-1yl and perhydro-2,4-dioxopyrimidin-1-yl ergoline derivatives", IL FARMACO, vol. 53, pp 293-304 (1998)

EXAMINER DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.